Core Viewpoint - TianKang Biological has shown significant growth in its performance for the first half of the year, with notable increases in revenue and profit metrics, despite mixed results across different business segments [2]. Financial Performance - The company achieved an operating revenue of 8.847 billion, a year-on-year increase of 10.68% [2] - Total profit reached 421 million, reflecting a year-on-year growth of 43.29% [2] - Net profit attributable to shareholders was 338 million, up 22.27% year-on-year [2] - Net profit excluding non-recurring gains and losses was 314 million, an increase of 16.17% year-on-year [2] Business Segment Performance - Feed business sales volume was 134.15 thousand tons, with sales revenue of 2.434 billion, a decline of 14.24% year-on-year [2] - Pig sales reached 1.5282 million heads, a growth of 9.05%, with sales revenue of 2.849 billion, down 0.95% year-on-year [2] - Animal vaccine business sales revenue was 482 million, with growth details not specified [2] - Protein oil business sales revenue was 1.449 billion, showing a significant increase of 97.60% year-on-year [2] - Corn storage business sales revenue was 1.305 billion, up 72.32% year-on-year [2] Cost Management and Strategic Developments - Self-breeding costs decreased to 12.55 per kilogram, with potential for further reduction as piglet prices decline [3] - The company is in the process of acquiring Qiangdu Livestock, which has shown strong operational performance and cost competitiveness [3] - The protein oil business has seen a significant increase in profitability, with a recent joint venture contributing positively [3] - The corn storage business has turned profitable after a period of losses, with expectations for continued good performance [3] - TianKang Pharmaceutical's listing progress is ongoing, with recent inquiries and updates planned [3]